Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1 / 2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

L. Telli, Melinda; C. Jensen, Kristin; Vinayak, Shaveta; W. Kurian, Allison; A. Lipson, Jafi; Flaherty, Patrick; M. Timms, Kirsten; Abkevich, Victor; Schackmann, Elizabeth; Wapnir, Irene; W. Carlson, Robert; Chang, Pei-Jen; A. Sparano, Joseph; Head, Bobbie; J. Goldstein, Lori; Haley, Barbara; R. Dakhil, Shaker; Reid, Julia; Hartman, Anne-Renee; Manola, Judith; M. Ford, James

doi:10.1200/jco.2014.57.0085

Public

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1 / 2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

Published in Journal of Clinical Oncology • Apr 6, 2015

Authors:

Melinda L. Telli

Kristin C. Jensen

Shaveta Vinayak

Abstract

PURPOSE: This study was designed to assess efficacy, safety, and predictors of response to iniparib in combination with gemcitabine and carboplatin in early-stage triple-negative and BRCA1/2 mutation-associated breast cancer. PATIENTS AND METHODS: This single-arm phase II study enrolled patients wit...

Subject

Medicine

Carboplatin

Gemcitabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!